Mycobacterium bovis epidural abscess following Bacillus Calmette-Guerin therapy for bladder cancer

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer

We present a rare case of tuberculous spondylitis following intravesical Bacillus Calmette-Guerin (BCG) therapy for bladder cancer. An 82-year-old man presented with low back pain. Past medical history revealed bladder cancer diagnosed and treated 16 months previously by intravesical BCG. Magnetic resonance imaging of the thoracic spine showed destruction of the T5 and T6 vertebrae and an epidu...

[Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].

Intracavitary instillation of Tokyo 172 strain Bacillas Calmette-Guerin was performed on 39 patients with superficial bladder cancer after contact Nd:YAG laser irradiation for tumors. The BCG group received intravesical instillation of 80 mg BCG at two week intervals for 6 months. Recurrence occurred in 7 of the 39 patients. In the 7 recurrent cases instillation of BCG had been discontinued aft...

Bacillus Calmette-Guerin and bladder cancer.

Bladder cancer is the second most common cancer of the urinary tract, and overall it is among the top 10 cancers in men. Transitional cell carcinoma (TCC) is the most common type, with the majority being superficial disease, i.e. the tumour has not gone beyond the lamina propria. The main problem with superficial TCC is the high recurrence rate. Various forms of treatment methods have been atte...

Symptomatic granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy for bladder cancer.

Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.

Transitional-cell carcinoma of the bladder is an aggressive and potentially fatal malignancy. In 1990, the US Food and Drug Administration approved the use of intravesicular bacillus CalmetteGuérin (BCG) for the treatment of superficial bladder cancer.1 BCG is a live, attenuated strain of Mycobacterium bovis (M. bovis) that has been used to treat transitional-cell carcinoma since 1976 and has b...